Affordable Access

A Randomized Phase 1 Dose Escalation Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Trabodenoson in Healthy Adult Volunteers.

Authors
  • Laties, Alan1
  • Rich, Cadmus C2
  • Stoltz, Randall3
  • Humbert, Vernon4
  • Brickman, Chaim2
  • McVicar, William2
  • Baumgartner, Rudolf A2
  • 1 1 Scheie Eye Institute , Philadelphia, Pennsylvania.
  • 2 2 Inotek Pharmaceuticals Corporation , Lexington, Massachusetts.
  • 3 3 Covance Global Clinical Pharmacology , Evansville, Indiana.
  • 4 4 Evansville Heart Center , Evansville, Indiana.
Type
Published Article
Journal
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
Publication Date
October 2016
Volume
32
Issue
8
Pages
548–554
Identifiers
PMID: 27046445
Source
Medline
Keywords
License
Unknown

Abstract

Ocular doses of trabodenoson up to 3,200 μg per eye were safe and well tolerated in the eye and resulted in no detectable systemic effects in healthy adult volunteers.

Report this publication

Statistics

Seen <100 times